200 related articles for article (PubMed ID: 32661603)
1. Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
Lathwal A; Kumar R; Arora C; Raghava GPS
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2743-2752. PubMed ID: 32661603
[TBL] [Abstract][Full Text] [Related]
2. Identifying prognostic biomarkers of non-small cell lung cancer by transcriptome analysis.
Xiong Y; Feng Y; Qiao T; Han Y
Cancer Biomark; 2020; 27(2):243-250. PubMed ID: 32083573
[TBL] [Abstract][Full Text] [Related]
3. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
4. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
6. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
7. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
[TBL] [Abstract][Full Text] [Related]
8. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
9. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.
Chen J; Chen H; Yang H; Dai H
Biomed Pharmacother; 2018 Apr; 100():233-239. PubMed ID: 29432994
[TBL] [Abstract][Full Text] [Related]
10. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
11. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
12. Survival-associated alternative splicing signatures in non-small cell lung cancer.
Zhao D; Zhang C; Jiang M; Wang Y; Liang Y; Wang L; Qin K; Rehman FU; Zhang X
Aging (Albany NY); 2020 Apr; 12(7):5878-5893. PubMed ID: 32282333
[TBL] [Abstract][Full Text] [Related]
13. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
Huang G; Zhang J; Gong L; Huang Y; Liu D
BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
[TBL] [Abstract][Full Text] [Related]
14. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
[TBL] [Abstract][Full Text] [Related]
16. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.
Lu C; Bera K; Wang X; Prasanna P; Xu J; Janowczyk A; Beig N; Yang M; Fu P; Lewis J; Choi H; Schmid RA; Berezowska S; Schalper K; Rimm D; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Nov; 2(11):e594-e606. PubMed ID: 33163952
[TBL] [Abstract][Full Text] [Related]
17. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
19. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
Liu T; Xu S; Liu X
Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
[TBL] [Abstract][Full Text] [Related]
20. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.
Thaiparambil J; Dong J; Grimm SL; Perera D; Ambati CSR; Putluri V; Robertson MJ; Patel TD; Mistretta B; Gunaratne PH; Kim MP; Yustein JT; Putluri N; Coarfa C; El-Zein R
Cancer Med; 2023 Jan; 12(1):584-596. PubMed ID: 35676822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
